| Year |
Citation |
Score |
| 2021 |
Rømer TB, Aasted MKM, Dabelsteen S, Groen A, Schnabel J, Tan E, Pedersen JW, Haue AD, Wandall HH. Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. British Journal of Cancer. PMID 34526666 DOI: 10.1038/s41416-021-01530-7 |
0.325 |
|
| 2019 |
Pedersen JW, Nøstdal A, Wandall HH. Multiplexed Detection of Autoantibodies to Glycopeptides Using Microarray. Methods in Molecular Biology (Clifton, N.J.). 2024: 199-211. PMID 31364051 DOI: 10.1007/978-1-4939-9597-4_12 |
0.353 |
|
| 2014 |
Pedersen JW, Gentry-Maharaj A, Nøstdal A, Fourkala EO, Dawnay A, Burnell M, Zaikin A, Burchell J, Papadimitriou JT, Clausen H, Jacobs I, Menon U, Wandall HH. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International Journal of Cancer. Journal International Du Cancer. 134: 2180-88. PMID 24122770 DOI: 10.1002/Ijc.28538 |
0.426 |
|
| 2013 |
Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, Blixt O, Fourkala EO, Bueti D, Dawnay A, Ford J, Desai R, David L, Trinder P, Acres B, et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British Journal of Cancer. 108: 2045-55. PMID 23652307 DOI: 10.1038/Bjc.2013.214 |
0.389 |
|
| 2011 |
Pedersen AE, Stryhn A, Justesen S, Harndahl M, Rasmussen S, Donskov F, Claesson MH, Pedersen JW, Wandall HH, Svane IM, Buus S. Wildtype p53-specific antibody and T-cell responses in cancer patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 629-40. PMID 21989411 DOI: 10.1097/Cji.0B013E3182281381 |
0.411 |
|
| 2011 |
Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, Chen C, Rhodes JM, Yu LG. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7035-46. PMID 21933892 DOI: 10.1158/1078-0432.Ccr-11-1462 |
0.352 |
|
| 2011 |
Pedersen JW, Bennett EP, Schjoldager KT, Meldal M, Holmér AP, Blixt O, Cló E, Levery SB, Clausen H, Wandall HH. Lectin domains of polypeptide GalNAc transferases exhibit glycopeptide binding specificity. The Journal of Biological Chemistry. 286: 32684-96. PMID 21768105 DOI: 10.1074/Jbc.M111.273722 |
0.401 |
|
| 2011 |
Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, Mandel U, Poulsen SS, Pedersen AE, Rasmussen S, Jess P, Clausen H, Wandall HH. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. International Journal of Cancer. Journal International Du Cancer. 128: 1860-71. PMID 21344374 DOI: 10.1002/Ijc.25778 |
0.459 |
|
| 2011 |
Pedersen JW, Wandall HH. Autoantibodies as Biomarkers in Cancer Labmedicine. 42: 623-628. DOI: 10.1309/Lm2T3Ou3Rzrthksn |
0.416 |
|
| 2010 |
Steentoft C, Schjoldager KT, Cló E, Mandel U, Levery SB, Pedersen JW, Jensen K, Blixt O, Clausen H. Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8). Glycoconjugate Journal. 27: 571-82. PMID 20721622 DOI: 10.1007/S10719-010-9301-6 |
0.429 |
|
| 2010 |
Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Research. 70: 1306-13. PMID 20124478 DOI: 10.1158/0008-5472.Can-09-2893 |
0.462 |
|
| Show low-probability matches. |